
On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).
The data demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months).